公开(公告)号：US09272999B2

公开(公告)日：2016-03-01

申请号：US14669303

申请日：2015-03-26

申请人： Merck Sharp & Dohme Corp.

发明人： John Y. L. Chung ,  Yanfeng Zhang ,  Aaron S. Cote ,  Jeremy Scott ,  Yekaterina Vaynshteyn

IPC分类号： C07D209/18

CPC分类号： C07D209/18 ,  C07B2200/13

摘要： The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.

公开(公告)号：US09012488B2

公开(公告)日：2015-04-21

申请号：US14186829

申请日：2014-02-21

申请人： Merck Sharp & Dohme Corp.

发明人： John Y. L. Chung ,  Yanfeng Zhang ,  Laura Artino ,  Aaron S. Cote ,  Donal Desmond ,  Jeremy Scott ,  Yekaterina Vaynshteyn

IPC分类号： A61K31/405 ,  C07D209/12 ,  C07D209/18

CPC分类号： C07D209/18 ,  C07B2200/13

摘要： The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.

摘要翻译： 本发明涉及式A化合物的多晶型物质：该化合物可用作胰高血糖素受体拮抗剂并用作用于治疗2型糖尿病和相关病症的药物活性成分，例如高血糖症，肥胖症，血脂异常和 代谢综合征。 包括水合物，半水合物，水合物和类似的多晶型物质。

公开(公告)号：US20150197490A1

公开(公告)日：2015-07-16

申请号：US14669303

申请日：2015-03-26

申请人： Merck Sharp & Dohme Corp.

发明人： John Y. L. Chung ,  Yanfeng Zhang ,  Aaron S. Cote ,  Jeremy Scott ,  Yekaterina Vaynshteyn

IPC分类号： C07D209/18

CPC分类号： C07D209/18 ,  C07B2200/13

摘要： The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.

摘要翻译： 本发明涉及式A化合物的多晶型物质：该化合物可用作胰高血糖素受体拮抗剂并用作用于治疗2型糖尿病和相关病症的药物活性成分，例如高血糖症，肥胖症，血脂异常和 代谢综合征。 包括水合物，半水合物，水合物和类似的多晶型物质。

公开(公告)号：US20140171480A1

公开(公告)日：2014-06-19

申请号：US14186829

申请日：2014-02-21

申请人： Merck Sharp & Dohme Corp.

发明人： John Y. L. Chung ,  Yanfeng Zhang ,  Laura Artino ,  Aaron S. Cote ,  Donal Desmond ,  Jeremy Scott ,  Yekaterina Vaynshteyn

IPC分类号： C07D209/18

CPC分类号： C07D209/18 ,  C07B2200/13

摘要： The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.

摘要翻译： 本发明涉及式A化合物的多晶型物质：该化合物可用作胰高血糖素受体拮抗剂并用作用于治疗2型糖尿病和相关病症的药物活性成分，例如高血糖症，肥胖症，血脂异常和 代谢综合征。 包括水合物，半水合物，水合物和类似的多晶型物质。